Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | CSF1R | P07333 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | MET | P08581 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 1/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.54 |
| ▸ | CDK8 | P49336 | 1/20 | 0.54 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.54 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.54 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27706637 | 0.89 | CCR1 (0.54) | AURKAABL1NTRK1LCKCSF1R | |
| SCHEMBL12684741 | 0.83 | RAB9A (0.63) | AURKAABL1NTRK1LCKCSF1R | |
| SCHEMBL26316729 | 0.81 | AURKA (0.54) | AURKAABL1NTRK1LCKCSF1R | |
| Hydrochloric Acid SCHEMBL31716140 | 0.81 | CYP11B1 (0.54) | KDM1ACYP11B1CYP11B2CYP3A4RAB9A | |
| SCHEMBL12569433 | 0.81 | GRM2 (0.49) | KDM1ACYP11B1CYP11B2RAB9ANPC1 | |
| SCHEMBL26316731 | 0.81 | AURKA (0.54) | AURKAABL1NTRK1LCKCSF1R | |
| SCHEMBL317352 | 0.81 | CYP11B1 (0.54) | AURKAABL1NTRK1LCKCSF1R | |
| SCHEMBL30083539 | 0.81 | CYP11B1 (0.59) | CYP11B1CYP11B2CYP3A4RAB9ANPC1 | |
| SCHEMBL1720975 | 0.81 | CYP11B1 (0.59) | CYP11B1CYP11B2CYP3A4RAB9ANPC1 | |
| SCHEMBL25167216 | 0.80 | AURKA (0.52) | AURKAABL1NTRK1LCKCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12022832-B2 | Compounds and methods for treating nematode infections | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2024-07-02 | — | — | US | disclosed |
| US-20170313697-A1 | PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AND USE THEREOF | GUANGDONG GOOD MEDICINE AND HEALTH TECHNOLOGY CO., LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| EP-1465613-A2 | COMBINATION OF MTP INHIBITORS OR APOB SECRETION INHIBITORS WITH FIBRATES FOR USE AS DRUGS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2004-10-13 | — | — | EP | disclosed |
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-08-28 | — | — | US | disclosed |
| WO-2003057205-A2 | COMBINATION OF MTP INHIBITORS OR APOB SECRETION INHIBITORS WITH FIBRATES FOR USE AS DRUGS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-07-17 | — | — | WO | disclosed |
| US-20030073836-A1 | Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-04-17 | — | — | US | disclosed |
| WO-2003004020-A1 | HETEROARYL CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS INHIBITORS OF THE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12022832-B2 | Compounds and methods for treating nematode infections | HNMT, NISCH, HRH2 | AURKA 4574/4885ABL1 1549/4885NTRK1 4669/4885 |
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | APOB, LIPC, MTPN | AURKA 3376/4885ABL1 3439/4885NTRK1 3998/4885 |
| US-20170313697-A1 | PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AND USE THEREOF | ABCG2, ABCC1, PNPO | AURKA 1239/4885ABL1 2091/4885NTRK1 1930/4885 |
| US-20030073836-A1 | Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | MTTP, CETP, CES1 | AURKA 3970/4885ABL1 2200/4885NTRK1 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.